www.fdanews.com/articles/206910-abbvie-and-alvotech-settle-over-alleged-stolen-trade-secrets-on-blockbuster-humira
AbbVie and Alvotech Settle Over Alleged Stolen Trade Secrets on Blockbuster Humira
March 10, 2022
AbbVie has settled with Alvotech over allegations that the Icelandic drugmaker tried to market a biosimilar version of AbbVie’s blockbuster rheumatoid arthritis medicine Humira (adalimumab) after allegedly stealing trade secrets about the drug through an AbbVie ex-employee.
The settlement stipulates that AbbVie will grant Alvotech a nonexclusive license to its Humira-related patents in the U.S. — but not until July 1, 2023.
Alvotech will pay royalties to AbbVie for licensing the patents “and acknowledges the validity and enforceability of the licensed patents,” according to the deal.